All 4Front Subsidiaries File for Court-Appointed Receiver
"The 4Front Board made this decision only as a last resort," said Chairman of the Board Kris Krane. "While we believe 4Front's cultivation and manufacturing operations are standouts and its retail stores have found exciting new ways to engage consumers, the liabilities on the Company's balance sheet coupled with a lack of available financing for operations have forced us to file for a voluntary receivership in order to pursue an orderly sale of the Company's businesses."
"The 4Front Board gave careful consideration to the duties owed to all stakeholders, and in the absence of other available alternatives, determined that it was in the best interests of the Company and its stakeholders to voluntarily request a receivership and court protection."
Further information regarding the proceedings may be obtained from the receiver once appointed. Foley Hoag LLP is serving as legal counsel to the Company.
The Company previously announced that, as a result of its failure to file its audited annual financial statements for the year ended December 31, 2024, and related management discussion and certifications, the Ontario Securities Commission had issued a failure-to-file cease trade order generally prohibiting its common stock from being traded in Canada. Due to that filing deficiency and the receivership petition, it is anticipated that the Company ultimately will be delisted from both the Canadian Securities Exchange and the OTCQB.
About 4Front Ventures Corp.
4Front is a national, vertically integrated multi-state cannabis operator with operations in Illinois and Massachusetts and facilities in Washington. Since its founding in 2011, 4Front has built a strong reputation for its high standards and low-cost cultivation and production methodologies earned through a track record of success in facility design, cultivation, genetics, growing processes, manufacturing, purchasing, distribution, and retail. To date, 4Front has successfully brought to market more than 20 different cannabis brands and over 1,800 products, which are strategically distributed through its fully owned and operated Mission dispensaries and retail outlets in its core markets. For more information, visit https://4frontventures.com/.
The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/all-4front-subsidiaries-file-for-court-appointed-receiver-302464032.html
SOURCE 4Front Ventures Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/23/c1678.html
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
Pulsar Helium Announces Major Flow Test Results at Jetstream #1, Topaz Project
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR TO BE TRANSMITTED, DISTRIBUTED TO, OR SENT BY, ANY NATIONAL OR RESIDENT OR CITIZEN OF ANY SUCH COUNTRIES OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION MAY CONTRAVENE LOCAL SECURITIES LAWS OR REGULATIONS. CASCAIS, Portugal, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF) ('Pulsar' or the 'Company'), a leading helium project development company, is delighted to report major natural flow test results at the Jetstream #1 appraisal well, part of the Topaz helium project in Minnesota, USA. These latest results mark a major leap in well performance, with natural flow rates more than tripling those recorded in 2024. A summary of the results is as follows: Thomas Abraham-James, President & CEO of Pulsar, commented: ' The deepening of the Jetstream #1 appraisal well to a total depth of 5,100 feet, penetrating the entire interpreted helium-bearing zone, has proven highly successful. The well is now naturally flowing at ~501 thousand cubic feet per day at 30 pounds per square inch WHP, more than three times the peak natural flow achieved in 2024. This result validates our subsurface model, significantly de-risks the Topaz project, and confirms the reservoir's outstanding productivity. This is especially exciting considering the 2024 gas analysis for the same well returned helium concentrations ranging from 8.7% to 14.5%. With further flow testing, including under well-head compression, and gas composition analyses to follow, we look forward to sharing further updates, and the results of Jetstream #2. These results underscore the immense opportunity at Topaz and signal the start of unlocking its full potential. ' Test Results and Analysis The Jetstream #1 well delivered a maximum natural flow rate of ~501 thousand cubic feet per day (Mcf/d) during open-flow testing on August 15, 2025. This was observed on a 38/64-inch choke at approximately 30 psi WHP, without compression assistance. By comparison, during initial appraisal in April 2024, Jetstream #1 reached a peak natural flow of ~150 Mcf/d at 34 psi. The improvement of more than threefold under near-identical pressure conditions highlights the effectiveness of recent wellbore clean-up and deepening and underscores the formation's strong productivity. Importantly, no formation water has been encountered, the gas has flowed as dry gas. In addition to the peak result, Jetstream #1 demonstrated stable long-duration flows, producing 150–300 Mcf/d for periods of 12–18 hours on smaller choke sizes. These sustained flows showed no significant decline and were followed by rapid pressure recovery, indicating excellent reservoir recharge capacity. Compression Testing and Expected Upside To further assess the well's maximum capacity, Pulsar is commencing a compression-assisted flow test. By reducing WHP via surface compression, flow rates are expected to increase significantly. For reference, compression applied during the February 2024 test program resulted in a maximum flow rate of ~821 Mcf/d. The current test is designed to validate Jetstream #1's full potential and provide key data for production facility design and future development planning. A Brief Explanation of Flow Testing Under 'Natural' Conditions and Under 'Compression' When a well produces under natural flow, the gas comes to surface on its own, pushed out purely by the pressure in the reservoir. It's a strong indicator of how much energy the reservoir holds. With compression, special surface equipment is used to lower the pressure at the wellhead, which makes it easier for the gas to flow out. This doesn't change the size of the reservoir, but it allows much higher flow rates and gives a clearer picture of the well's maximum production potential. About the Topaz Project The Topaz project is located in northern Minnesota, USA where Pulsar is the first mover and holds exclusive leases. Drilling at the Jetstream #1 appraisal well reached total depth ('TD') of 5,100 feet (1,555 metres) on January 11, 2025, successfully penetrating the entire interpreted helium-bearing reservoir and beyond. The Jetstream #1 appraisal well previously reached TD of 2,200 feet (671 metres) on February 27, 2024, identifying top-tier helium concentrations of up to 14.5%, well above the 0.3% widely accepted economic threshold, and flowed at a rate of 821,000 cubic feet per day under well-head compression. Drilling of the Jetstream #2 appraisal well was completed on February 1, 2025, reaching a TD of 5,638 feet (1,718 metres). These activities will progress Pulsar's strategy become a producer of helium, addressing increasing global demand. On behalf of Pulsar Helium Inc. 'Thomas Abraham-James' President, CEO and Director Further Information: Pulsar Helium Inc. [email protected] + 1 (218) 203-5301 (USA/Canada) +44 (0) 2033 55 9889 (United Kingdom) Strand Hanson Limited (Nominated & Financial Adviser, and Joint Broker) Ritchie Balmer / Rob Patrick / Richard Johnson +44 (0) 207 409 3494 OAK Securities* (Joint Broker) Jerry Keen (Corporate Broking) / Henry Clarke (Institutional Sales) / Dillon Anadkat (Corporate Advisory) [email protected] +44 203 973 3678 *OAK Securities is the trading name of Merlin Partners LLP, a firm incorporated in the United Kingdom and regulated by the UK Financial Conduct Authority. Yellow Jersey PR Limited (Financial PR) Charles Goodwin / Annabelle Wills +44 777 5194 357 [email protected] About Pulsar Helium Inc. Pulsar Helium Inc. is a publicly traded company listed on the AIM market of the London Stock Exchange and the TSX Venture Exchange with the ticker PLSR, as well as on the OTCQB with the ticker PSRHF. Pulsar's portfolio consists of its flagship Topaz helium project in Minnesota, USA, and the Tunu helium project in Greenland. Pulsar is the first mover in both locations with primary helium occurrences not associated with the production of hydrocarbons identified at each. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Qualified Person Signoff In accordance with the AIM Note for Mining and Oil and Gas Companies, the Company discloses that Thomas Abraham-James, President, CEO and Director of the Company has reviewed the technical information contained herein. Mr. Abraham-James has approximately 20 years in the mineral exploration industry, is a Chartered Professional Fellow of the Australasian Institute of Mining and Metallurgy (FAusIMM CP (Geo)), a Fellow of the Society of Economic Geologists and a Fellow of the Geological Society of London. Forward-Looking Statements This news release contains forward-looking information within the meaning of Canadian securities legislation (collectively, 'forward-looking statements') that relate to the Company's current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, through the use of words or phrases such as 'will likely result', 'are expected to', 'expects', 'will continue', 'is anticipated', 'anticipates', 'believes', 'estimated', 'intends', 'plans', 'forecast', 'projection', 'strategy', 'objective' and 'outlook') are not historical facts and may be forward-looking statements. Forward-looking statements herein include, but are not limited to, statements relating to the completion of the flow testing and pressure build up tests of Jetstream #2, the timing of completion of the flow testing and pressure testing; the potential impact of the drill results, flow testing and pressure testing on the next iteration of the resource estimate; the potential of CO2 as a valuable by-product of the Company's future helium production; and the potential for future wells. Forward-looking statements may involve estimates and are based upon assumptions made by management of the Company, including, but not limited to, the Company's capital cost estimates, management's expectations regarding the availability of capital to fund the Company's future capital and operating requirements and the ability to obtain all requisite regulatory approvals. No reserves have been assigned in connection with the Company's property interests to date, given their early stage of development. The future value of the Company is therefore dependent on the success or otherwise of its activities, which are principally directed toward the future exploration, appraisal and development of its assets, and potential acquisition of property interests in the future. Un-risked Contingent and Prospective Helium Volumes have been defined at the Topaz Project. However, estimating helium volumes is subject to significant uncertainties associated with technical data and the interpretation of that data, future commodity prices, and development and operating costs. There can be no guarantee that the Company will successfully convert its helium volume to reserves and produce that estimated volume. Estimates may alter significantly or become more uncertain when new information becomes available due to for example, additional drilling or production tests over the life of field. As estimates change, development and production plans may also vary. Downward revision of helium volume estimates may adversely affect the Company's operational or financial performance. Helium volume estimates are expressions of judgement based on knowledge, experience and industry practice. These estimates are imprecise and depend to some extent on interpretations, which may ultimately prove to be inaccurate and require adjustment or, even if valid when originally calculated, may alter significantly when new information or techniques become available. As further information becomes available through additional drilling and analysis the estimates are likely to change. Any adjustments to volume could affect the Company's exploration and development plans which may, in turn, affect the Company's performance. The process of estimating helium resources is complex and requires significant decisions and assumptions to be made in evaluating the reliability of available geological, geophysical, engineering, and economic date for each property. Different engineers may make different estimates of resources, cash flows, or other variables based on the same available data. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward- looking statements. Such risks and uncertainties include, but are not limited to, that Pulsar may be unsuccessful in completing the flow testing and pressure testing of Jetstream #2, in drilling commercially productive wells; the uncertainty of resource estimation; operational risks in conducting exploration, including that flow-testing, pressure testing and drill costs may be higher than estimates ; commodity prices; health, safety and environmental factors; and other factors set forth above as well as under 'Cautionary Note Regarding Forward Looking Statements and Market and Industry Data' and 'Risk Factors' in the AIM Admission Document published on October 14, 2024 found on the Company's web site at and the Company's Annual Information Form dated as of July 31, 2025 found on the Company's profile at Forward-looking statements contained in this news release are as of the date of this news release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for the Company to predict all of them or assess the impact of each such factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. No assurance can be given that the forward-looking statements herein will prove to be correct and, accordingly, investors should not place undue reliance on forward-looking statements. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.
Associated Press
4 minutes ago
- Associated Press
Empire Metals Limited Announces Drilling Outlines Large, High-Grade Zone
Major Drilling Campaign Outlines Large, High-Grade Zone LONDON, UNITED KINGDOM / ACCESS Newswire / August 18, 2025 / Empire Metals Limited,theAIM-quoted and OTCQB-tradedexploration and development company,is pleased to report outstanding assay results from its latest drilling campaign at the Pitfield Project in Western Australia ('Pitfield' or the 'Project'). This programme, focused on the in-situ weathered cap at the Thomas Prospect, has delivered some of the highest titanium dioxide ('TiO₂') grades recorded to date and will underpin the Company's maiden JORC-compliant Mineral Resource Estimate ('MRE'). Highlights Shaun Bunn, Managing Director, said:"These results confirm the exceptional scale and grade of titanium mineralisation at Thomas. The continuity of high-grade mineralisation near surface is particularly exciting for future mine development. With assays received ahead of schedule, we can now accelerate resource modelling and move rapidly towards announcing our maiden MRE.' MRE Drilling Programme - Key Results Since commencing the maiden drilling campaign at Pitfield on 27 March 2023 Empire has completed 382 drill holes for a total 32,265 metres (refer Figure 1) comprising: The latest May-June campaign comprised: Figure 1. Grey-scale magnetics overlain by airborne gravity data showing RC, AC and diamond drillhole collar locations and JORC Exploration Target areas. During the campaign all drill holes were subsampled on a 2m interval, resulting in over 5,000 drill samples being collected, logged by our on-site team of geologists and then prepared for shipment to Intertek's Perth based analytical laboratory. The analytical assay results have now been received, showing continuous TiO2-rich mineralisation across the overall drillhole grid, which extends 5.2km by 2.6km and totals an area of 1,352 hectares (refer Figure 2). The drilling has confirmed the presence of a large, high-grade central core at the Thomas prospect, this target being selected as the basis for the maiden MRE due to the extensive, thick and high-grade titanium mineralisation known to be hosted within the broad, in-situ weathered zone. Whilst over 90% of all drillhole sample assays show mineralisation well above a 2% TiO2 cut-off grade this central high-grade core, extends over 3.6km north-south, averages around 6% TiO2 (refer Table 1). Table 1. Breakdown of drillhole assay results by average grade of drillhole and percentage of total drilling. Significant analytical assay results for each drillhole above 6% TiO2 are reported in Table 2 further below. Figure 2. RC and AC drill hole collar locations within the Thomas Prospect priority area. Strategic Significance The May-June campaign marked a major milestone in the development of Pitfield, laying the foundation for a globally significant MRE and enabling the identification of near-surface, high grade zones to support the development of mine planning and ore scheduling as part of upcoming economic evaluation studies. Table 2. Significant Intercepts above 6% TiO2. The Pitfield Titanium Project Located within the Mid-West region of Western Australia, near the northern wheatbelt town of Three Springs, the Pitfield titanium project lies 313km north of Perth and 156km southeast of Geraldton, the Mid West region's capital and major port. Western Australia is a Tier 1 mining jurisdiction, with mining-friendly policies, stable government, transparency, and advanced technology expertise. Pitfield has existing connections to port (both road & rail), HV power substations, and is nearby to natural gas pipelines as well as a green energy hydrogen fuel hub, which is under planning and development (refer Figure 3). Figure 3. Pitfield Project Location showing theMid-West Region Infrastructure and Services Competent Person Statement The technical information in this report that relates to the Pitfield Project has been compiled by Mr Andrew Faragher, an employee of Empire Metals Australia Pty Ltd, a wholly owned subsidiary of Empire. Mr Faragher is a Member of the Australian Institute of Mining and Metallurgy. Mr Faragher has sufficient experience that is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaken to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. Mr Faragher consents to the inclusion in this release of the matters based on his information in the form and context in which it appears. Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018, until the release of this announcement. **ENDS** For further information please visit or contact: About Empire Metals Limited Empire Metals is an AIM-listed and OTCQB-traded exploration and resource development company (LON: EEE) with a primary focus on developing Pitfield, an emerging giant titanium project in Western Australia. The high-grade titanium discovery at Pitfield is of unprecedented scale, with airborne surveys identifying a massive, coincident gravity and magnetics anomaly extending over 40km by 8km by 5km deep. Drill results have indicated excellent continuity in grades and consistency of the mineralised beds and confirm that the sandstone beds hold the higher-grade titanium dioxide (TiO₂) values within the interbedded succession of sandstones, siltstones and conglomerates. The Company is focused on two key prospects (Cosgrove and Thomas), which have been identified as having thick, high-grade, near-surface, bedded TiO₂ mineralisation, each being over 7km in strike length. An Exploration Target* for Pitfield was declared in 2024, covering the Thomas and Cosgrove mineral prospects, and was estimated to contain between 26.4 to 32.2 billion tonnes with a grade range of 4.5 to 5.5% TiO2. Included within the total Exploration Target* is a subset that covers the weathered sandstone zone, which extends from surface to an average vertical depth of 30m to 40m and is estimated to contain between 4.0 to 4.9 billion tonnes with a grade range of 4.8 to 5.9% TiO2. The Exploration Target* covers an area less than 20% of the overall mineral system at Pitfield which demonstrates the potential for significant further upside. Empire is now accelerating the economic development of Pitfield, with a vision to produce a high-value titanium metal or pigment quality product at Pitfield, to realise the full value potential of this exceptional deposit. The Company also has two further exploration projects in Australia; the Eclipse Project and the Walton Project in Western Australia, in addition to three precious metals projects located in a historically high-grade gold producing region of Austria. *The potential quantity and grade of the Exploration Target is conceptual in nature. There has been insufficient exploration to estimate a Mineral Resource and it is uncertain if further exploration will result in the estimation of a Mineral Resource. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Empire Metals Limited press release
Associated Press
8 minutes ago
- Associated Press
Genflow Biosciences PLC Announces Company Update on Dog Trials
Genflow Advances World's First Longevity Gene Therapy Trial in Dogs with No Adverse Effects Reported LONDON, UK / ACCESS Newswire / August 18, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ('Genflow' or 'the Company'), the only publicly listed longevity company in Europe, provides an update on its Dog Aging (GF-1004) study, a proof-of-concept clinical trial evaluating the safety and efficacy of its proprietary SIRT6-centenarian gene therapy for age-related decline in elderly dogs. The randomized, controlled trial, conducted with CRO Syngene, involves 28 beagles aged 10+ years. In March, recipients received three different modalities of SIRT6 gene therapy with no ill or adverse effects, while controls remain untreated. The dogs will now enter a five-month follow-up period expected to conclude in January 2026. The strategic goal of this proof-of-concept trial is to generate compelling preclinical data that will enable a licensing agreement with a leading Animal Health company. GF-1004 is a first-in-class gene therapy candidate targeting fundamental aging mechanisms shared by both dogs and humans. By intervening at the mitochondrial and epigenetic levels, GF-1004 offers the potential to not only extend lifespan, but also improve the quality of life in companion animals, a rapidly growing, high-value market segment. Study objectives are to: 1. Confirm feasibility of GF-1004 administration in the target population. 2. Validate safety and efficacy at the proposed administered dose. 3. Demonstrate multi-dimensional benefits relevant to both clinical outcomes and consumer appeal, including: Translational Potential Since dogs and humans share conserved aging pathways, success in this trial will provide a strong foundation for expansion into human health applications, unlocking additional markets in longevity therapeutics. Dr. Eric Leire, CEO of Genflow, commented: 'Now that all dogs have received the treatment without any adverse events, we've taken an important step in confirming the treatment's safety profile. We are fully focused on advancing GF-1004 to secure a partnership with an animal health company, combining scientific and commercial expertise to pave the way for a new class of therapeutic medicines for dogs. Our shared goal is to extend the healthspan of dogs, and we believe this study will demonstrate the safety and potential efficacy of GF-1004 while opening the door to broader applications of our proprietary platform in age-related diseases in both companion animals and, ultimately, in humans.' Contacts About Genflow Biosciences Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs planned for 2025, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit and follow the Company on LinkedIn and X. DISCLAIMER The contents of this announcement have been prepared by, and are the sole responsibility of, the Company. This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words 'anticipate', 'believe', 'continue', 'could', 'estimate', 'expect', 'intend', 'may', 'might', 'plan', 'possible', 'potential', 'predict', 'project', 'seek', 'should', 'would' and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions. Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit SOURCE: Genflow Biosciences PLC press release
